(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 19.55% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.06%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Transmedics Group's revenue in 2026 is $605,494,000.On average, 16 Wall Street analysts forecast TMDX's revenue for 2026 to be $25,861,303,858, with the lowest TMDX revenue forecast at $24,502,926,798, and the highest TMDX revenue forecast at $26,966,528,829. On average, 15 Wall Street analysts forecast TMDX's revenue for 2027 to be $30,704,123,890, with the lowest TMDX revenue forecast at $28,695,029,335, and the highest TMDX revenue forecast at $33,136,167,666.
In 2028, TMDX is forecast to generate $35,468,734,334 in revenue, with the lowest revenue forecast at $31,985,320,435 and the highest revenue forecast at $39,859,448,062.